SH3BP1: A Potential Drug Target and Biomarker forShaker-Induced Seizures

Target Name: SH3BP1

NCBI ID: G23616

SH3BP1

SH3BP1: A Potential Drug Target and Biomarker forShaker-Induced Seizures

Shaker-induced seizures are a type of epilepsy that can be characterized by recurrent, Brief, Intractable episodes of muscle convulsions that can cause significant distress and disability in the affected individual. The underlying cause of these seizures is not always well understood, but recent studies have identified several potential drug targets and biomarkers that may be involved in their development and treatment. One of these targets is the protein SH3BP1, which is a member of the SH3 protein family and has been shown to play a role in the regulation of epilepsy. In this article, we will explore the potential implications of SH3BP1 as a drug target and biomarker for shake-induced seizures.

The SH3 protein family is a conserved group of transmembrane proteins that contain a characteristic protein domain known as the SH3 domain. This domain is composed of a highly conserved amino acid sequence that includes a leucine-rich region, a catalytic tyrosine residue, and a carboxylic acid residue. The SH3 domain is thought to play a key role in the regulation of various cellular processes, including protein-protein interactions, signaling pathways, and intracellular signaling cascades.

One of the functions of the SH3 protein family is to regulate protein-protein interactions, which are critical for the regulation of cellular processes such as cell growth, differentiation, and survival. One of the well-known functions of the SH3 protein family is the regulation of the protein tyrosine kinase (PTK) family, which is a family of enzymes that regulate the phosphorylation of tyrosine residues on target proteins. The SH3BP1 protein, in particular, has been shown to play a role in the regulation of PTK-mediated signaling pathways, including the JAK/STAT3 signaling pathway.

Shake-induced seizures have been treated with a variety of medications, including anticonvulsants, benzodiazepines, and ketogenic diets. However, the exact underlying cause of these seizures remains unclear, and the development of new treatments remains a major goal in the field of epilepsy. SH3BP1 has been shown to play a role in the regulation of epilepsy, and its potential as a drug target or biomarker makes it an attractive target for researchers to investigate further.

In recent years, researchers have been interested in exploring the potential of drugs that target the SH3BP1 protein. One of the main advantages of these drugs is that they can act on multiple cellular processes, including the regulation of protein-protein interactions, the regulation of intracellular signaling cascades, and the regulation of protein synthesis. This makes them useful for treating a variety of diseases, including epilepsy.

One of the drugs that has been shown to act on the SH3BP1 protein is topiramate. Topiramate is an anti-epileptic drug that is currently in use for the treatment of epilepsy, bipolar disorder, and other conditions. It works by inhibiting the activity of the SH3BP1 protein, which has been shown to play a role in the regulation of intracellular signaling cascades, including the JAK/STAT3 signaling pathway.

In addition to topiramate, researchers have also been interested in exploring the potential of other drugs that target the SH3BP1 protein. These drugs include a variety of small molecules, including inhibitors of the SH3BP1 protein itself, as well as drugs that target the protein's downstream targets . One of the most promising of these drugs is a small molecule called S380560, which is currently being investigated for its potential as a treatment for epilepsy.

While the SH3BP1 protein is an attractive target for

Protein Name: SH3 Domain Binding Protein 1

Functions: GTPase activating protein (GAP) which specifically converts GTP-bound Rho-type GTPases including RAC1 and CDC42 in their inactive GDP-bound form. By specifically inactivating RAC1 at the leading edge of migrating cells, it regulates the spatiotemporal organization of cell protrusions which is important for proper cell migration (PubMed:21658605). Also negatively regulates CDC42 in the process of actin remodeling and the formation of epithelial cell junctions (PubMed:22891260). Through its GAP activity toward RAC1 and/or CDC42 plays a specific role in phagocytosis of large particles. Specifically recruited by a PI3 kinase/PI3K-dependent mechanism to sites of large particles engagement, inactivates RAC1 and/or CDC42 allowing the reorganization of the underlying actin cytoskeleton required for engulfment (PubMed:26465210). It also plays a role in angiogenesis and the process of repulsive guidance as part of a semaphorin-plexin signaling pathway. Following the binding of PLXND1 to extracellular SEMA3E it dissociates from PLXND1 and inactivates RAC1, inducing the intracellular reorganization of the actin cytoskeleton and the collapse of cells (PubMed:24841563)

The "SH3BP1 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about SH3BP1 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets